Détail d'une personne de l'annuaire - fr | Cancéropôle Est, la recherche innovante dans la lutte contre le cancer

Multiparametric renal function assessment in cirrhotic patients shows high prevalence of medically actionable changes in multiple modules.

Belmonte R, Silva-Rodriguez M, Barbé F, Bensenane M, Haghenejad V, Vrillon I, Alla A, Flahault A, Kormann R, Corbel A, Aitdjafer Z, Quilliot D, Derain-Dubourg L, Namour F, Guéant JL, Bronowicki JP, Oussalah A

Hepatol Res. 2024 04 25;:

Prevalence of hepatitis C, hepatitis B and HIV and their therapeutic management in a French public psychiatric hospital.

Icole F, Haghnejad V, Jeannoel C, Besançon P, Boulanger F, Bronowicki JP

Encephale. 2024 02 16;:

Serum infrared spectral profile is predictive of the degree of hepatic fibrosis in chronic hepatitis C patients.

Thiéfin G, Bertrand D, Untereiner V, Garnotel R, Bronowicki JP, Sockalingum GD

Spectrochim Acta A Mol Biomol Spectrosc. 2023 09 25;305:123433

Unresectable hepatocellular carcinoma at dawn of immunotherapy era: real-world data from the French prospective CHIEF cohort.

Nguyen-Khac E, Nahon P, Ganry O, Ben Khadhra H, Merle P, Amaddeo G, Ganne-Carrie N, Silvain C, Peron JM, Mathurin P, Anty R, Uguen T, Decaens T, Riachi G, Bouattour M, Baron A, Bronowicki JP, Pageaux GP, Rosmorduc O, Ducournau G, Gilberg M, Tanang A, Dupin J, Gilbert-Marceau A, Blanc JF,

Eur J Gastroenterol Hepatol. 2023 08 14;:

Impact of adjuvant sorafenib treatment after local ablation for HCC in the phase II SORAMIC trial.

Seidensticker M, Öcal O, Schütte K, Malfertheiner P, Berg T, Loewe C, Klümpen HJ, van Delden O, Ümütlü MR, Ben Khaled N, de Toni EN, Seidensticker R, Aghdassi A, Tran A, Bronowicki JP, Peynircioglu B, Sangro B, Pech M, Ricke J

JHEP Rep. 2023 05;5(5):100699

Atezolizumab plus bevacizumab in advanced hepatocellular carcinoma after treatment failure with multikinase inhibitors.

Haghnejad V, Muller M, Blaise L, Gerolami R, Bouattour M, Assenat E, Manfredi S, Peron JM, Burcheri-Curatolo A, Lopez A, Ressiot E, Nahon P, Bronowicki JP

Dig Liver Dis. 2023 04 3;:

TACE and conformal radiotherapy . TACE alone for hepatocellular carcinoma: A randomised controlled trial.

Féray C, Campion L, Mathurin P, Archambreaud I, Mirabel X, Bronowicki JP, Rio E, Perret C, Mineur L, Oberti F, Touchefeu Y, Gournay J, Regnault H, Edeline J, Rode A, Hillion P, Blanc JF, Khac EN, Azoulay D, Luciani A, Preglisasco AG, Faurel-Paul E, Auble H, Mornex F, Merle P

JHEP Rep. 2023 04;5(4):100689

Predictors of the utility of clinical exome sequencing as a first-tier genetic test in patients with Mendelian phenotypes: results from a referral center study on 603 consecutive cases.

Alix T, Chéry C, Josse T, Bronowicki JP, Feillet F, Guéant-Rodriguez RM, Namour F, Guéant JL, Oussalah A

Hum Genomics. 2023 02 5;17(1):5

An observational, prospective, multicenter study on the utilization and effectiveness of elbasvir-grazoprevir treatment association for chronic hepatitis C in France (ZEPHYR study).

Bronowicki JP, Miailhes P, Hanslik B, Ouzan D, Larrey D, Riachi G, Truchi R, Jouannaud V, Pospait D, Abergel A, Causse X, Perot S, Skrzypski J, De Hautecloque A, Spampinato A, Mariot P, Sogni P,

Health Sci Rep. 2023 01;6(1):e619

Triggering Receptors Expressed on Myeloid Cells 1 : Our New Partner in Human Oncology?

Muller M, Haghnejad V, Lopez A, Tiotiu A, Renaud S, Derive M, Bronowicki JP

Front Oncol. 2022 07 8;12:927440

Prediction of hepatocellular carcinoma in Hepatitis C patients with advanced fibrosis after sustained virologic response.

Azzi J, Dorival C, Cagnot C, Fontaine H, Lusivika-Nzinga C, Leroy V, De Ledinghen V, Tran A, Zoulim F, Alric L, Gournay J, Bronowicki JP, Decaens T, Riachi G, Mikhail N, Soliman R, Shiha G, Pol S, Carrat F, Ganne-Carrié N,

Clin Res Hepatol Gastroenterol. 2022 Apr 8;:101923

The Immune Landscape of Human Pancreatic Ductal Carcinoma: Key Players, Clinical Implications, and Challenges.

Muller M, Haghnejad V, Schaefer M, Gauchotte G, Caron B, Peyrin-Biroulet L, Bronowicki JP, Neuzillet C, Lopez A

Cancers (Basel). 2022 Feb 16;14(4):

Clinical outcomes after treatment with direct antiviral agents: beyond the virological response in patients with previous HCV-related decompensated cirrhosis.

Pageaux GP, Nzinga CL, Ganne N, Samuel D, Dorival C, Zoulim F, Cagnot C, Decaens T, Thabut D, Asselah T, Mathurin P, Habersetzer F, Bronowicki JP, Guyader D, Rosa I, Leroy V, Chazouilleres O, de Ledinghen V, Bourliere M, Causse X, Cales P, Metivier S, Loustaud-Ratti V, Riachi G, Alric L, Gelu-Simeon M, Minello A, Gournay J, Geist C, Tran A, Abergel A, Portal I, d'Alteroche L, Raffi F, Fontaine H, Carrat F, Pol S,

BMC Infect Dis. 2022 Jan 27;22(1):94

ABO blood group does not influence Child-Pugh A cirrhosis outcome: An observational study from CIRRAL and ANRS CO12 CIRVIR cohorts.

Ollivier-Hourmand I, Repesse Y, Nahon P, Chaffaut C, Dao T, Nguyen TN, Marcellin P, Roulot D, De Ledinghen V, Pol S, Guyader D, Archambeaud I, Zoulim F, Oberti F, Tran A, Bronowicki JP, D'Alteroche L, Ouzan D, Peron JM, Zarski JP, Bourliere M, Larrey D, Louvet A, Cales P, Abergel A, Mathurin P, Mallat A, Blanc JF, Nguyen-Khac E, Riachi G, Alric L, Serfaty L, Antonini T, Moreno C, Attali P, Thabut D, Pilette C, Grange JD, Silvain C, Carbonell N, Bernard-Chabert B, Goria O, Wartelle C, Moirand R, Christidis C, Perlemuter G, Ozenne V, Henrion J, Hillaire S, Di Martino V, Amiot X, Sutton A, Barget N, Chevret S, Ganne-Carrie N,

Liver Int. 2022 Jan 13;:

Common genetic variation in alcohol-related hepatocellular carcinoma: a case-control genome-wide association study.

Trépo E, Caruso S, Yang J, Imbeaud S, Couchy G, Bayard Q, Letouzé E, Ganne-Carrié N, Moreno C, Oussalah A, Féray C, Blanc JF, Clément B, Hillon P, Boursier J, Paradis V, Calderaro J, Gnemmi V, Nault JC, Guéant JL, Devière J, Archambeaud I, Vitellius C, Turlin B, Bronowicki JP, Gustot T, Sutton A, , Ziol M, Nahon P, Zucman-Rossi J

Lancet Oncol. 2021 Dec 10;:

Health-related quality of life in locally advanced hepatocellular carcinoma treated by either radioembolisation or sorafenib (SARAH trial).

Pereira H, Bouattour M, Dioguardi Burgio M, Assenat E, Grégory J, Bronowicki JP, Chatellier G, Vilgrain V,

Eur J Cancer. 2021 Jul 6;154:46-56

Full-length genome sequencing of RNA viruses-How the approach can enlighten us on hepatitis C and hepatitis E viruses.

Laugel E, Hartard C, Jeulin H, Berger S, Venard V, Bronowicki JP, Schvoerer E

Rev Med Virol. 2021 Jul;31(4):e2197

Expected outcomes and patients' selection before chemoembolization-"Six-and-Twelve or Pre-TACE-Predict" scores may help clinicians: Real-life French cohorts results.

Adhoute X, Larrey E, Anty R, Chevallier P, Penaranda G, Tran A, Bronowicki JP, Raoul JL, Castellani P, Perrier H, Bayle O, Monnet O, Pol B, Bourliere M

World J Clin Cases. 2021 Jun 26;9(18):4559-4572

Predictive Factors for Hepatocellular Carcinoma in Chronic Hepatitis B Using Structural Equation Modeling: A Prospective Cohort Study.

Lam L, Fontaine H, Bourliere M, Lusivika-Nzinga C, Dorival C, Thabut D, Zoulim F, Habersetzer F, Asselah T, Duclos-Vallee JC, Bronowicki JP, Mathurin P, Decaens T, Ganne N, Guyader D, Leroy V, Rosa I, Ledinghen V, Cales P, Causse X, Larrey D, Chazouilleres O, Gelu-Simeon M, Loustaud-Ratti V, Metivier S, Alric L, Riachi G, Gournay J, Minello A, Tran A, Geist C, Abergel A, Raffi F, D'alteroche L, Portal I, Lapidus N, Pol S, Carrat F,

Clin Res Hepatol Gastroenterol. 2021 Apr 27;:101713

Variability in molecular characteristics of Hepatitis E Virus quasispecies could modify viral surface properties and transmission.

Hartard C, Fenaux H, Gentilhomme A, Murray JM, Akand E, Laugel E, Berger S, Maul A, de Rougemont A, Jeulin H, Remen T, Bensenane M, Bronowicki JP, Gantzer C, Bertrand I, Schvoerer E

J Viral Hepat. 2021 Apr 20;:

Phase 2 trial comparing sorafenib, pravastatin, their combination or supportive care in HCC with Child-Pugh B cirrhosis.

Blanc JF, Khemissa F, Bronowicki JP, Monterymard C, Perarnau JM, Bourgeois V, Obled S, Abdelghani MB, Mabile-Archambeaud I, Faroux R, Seitz JF, Locher C, Senellart H, Villing AL, Audemar F, Costentin C, Deplanque G, Manfredi S, Edeline J,

Hepatol Int. 2021 Jan 9;:

Impact of Extrahepatic Metastases on Overall Survival in Patients with Advanced Liver Dominant Hepatocellular Carcinoma: A Subanalysis of the SORAMIC Trial.

Schütte K, Schinner R, Fabritius MP, Möller M, Kuhl C, Iezzi R, Öcal O, Pech M, Peynircioglu B, Seidensticker M, Sharma R, Palmer D, Bronowicki JP, Reimer P, Malfertheiner P, Ricke J

Liver Cancer. 2020 Dec;9(6):771-786

"Six-and-twelve" score for outcome prediction of hepatocellular carcinoma following transarterial chemoembolization. In-depth analysis from a multicenter French cohort.

Adhoute X, Pénaranda G, Raoul JL, Bronowicki JP, Anty R, Bourlière M

World J Hepatol. 2020 Aug 27;12(8):525-532

Fatty acid composition of the erythrocyte membrane and risk of hepatocellular carcinoma in cirrhotic patients.

Mouillot T, Rizk M, Pais de Barros JP, Gilloteau A, Busson A, Bernard-Chabert B, Thiefin G, Barraud H, Bronowicki JP, Richou C, Di Martino V, Doffoel M, Minello A, Latournerie M, Jouve JL, Brondel L, Brindisi MC, Petit JM, Hillon P, Cottet V,

Aliment. Pharmacol. Ther.. 2020 Aug 11;:

Personalized surveillance for hepatocellular carcinoma in cirrhosis - using machine learning adapted to HCV status.

Audureau E, Carrat F, Layese R, Cagnot C, Asselah T, Guyader D, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Chazouillères O, Mallat A, Grangé JD, Attali P, d'Alteroche L, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Pol S, Nahon P, Nahon P, Marcellin P, Guyader D, Pol S, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Chazouillères O, Mallat A, Grangé JD, Attali P, Louis d'Alteroche, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V,

J. Hepatol.. 2020 Jun 29;:

Absence of impact of direct acting antivirals for hepatitis C virus on recurrent hepatocellular carcinoma tumor growth in the AFEF/ANRS CO22 Hepather cohort.

Vallet-Pichard A, Correas JM, Dorival C, Zoulim F, Tran A, Bourlière M, Calès P, Guyader D, Bronowicki JP, Larrey D, Hezode C, Loustaud-Ratti V, Gournay J, de Ledinghen V, Asselah T, Ganne N, Metivier S, Chazouillères O, Leroy V, Rosa I, Samuel D, Mathurin P, Cagnot C, Fontaine H, Carrat F, Pol S,

Clin Res Hepatol Gastroenterol. 2020 Jun 25;:

Sofosbuvir-based regimens are suboptimal in patients with genotype 2 chronic hepatitis C infection: Real-life experience from the HEPATHER ANRS CO22 cohort.

de Lédinghen V, Lusivika-Nzinga C, Bronowicki JP, Zoulim F, Larrey D, Metivier S, Tran A, Marcellin P, Samuel D, Chazouillères O, Chevaliez S, Dorival C, Fontaine H, Pawlotsky JM, Carrat F, Pol S,

J. Viral Hepat.. 2020 May 21;:

The deficit in folate and vitamin B12 triggers liver macrovesicular steatosis and inflammation in rats with dextran sodium sulfate-induced colitis.

Harb Z, Deckert V, Bressenot AM, Christov C, Guéant-Rodriguez RM, Raso J, Alberto JM, de Barros JP, Umoret R, Biroulet LP, Lagrost L, Bronowicki JP, Guéant JL

J. Nutr. Biochem.. 2020 May 20;84:108415

Evaluation of Point Shear Wave Elastography Using Acoustic Radiation Force Impulse Imaging for Longitudinal Fibrosis Assessment in Patients with HBeAg-Negative HBV Infection.

Graf C, Mondorf A, Knop V, Peiffer KH, Dietz J, Friess J, Wedemeyer H, Buggisch P, Mauss S, Berg T, Rausch M, Sprinzl M, Klinker H, Hinrichsen H, Bronowicki JP, Haag S, Hüppe D, Lutz T, Poynard T, Zeuzem S, Friedrich-Rust M, Sarrazin C, Vermehren J

J Clin Med. 2019 Dec 2;8(12):

Efficacy and safety of elbasvir/grazoprevir for 8 or 12 weeks for hepatitis C virus: genotype 4 infection: a randomized study.

Asselah T, Pol S, Hezode C, Loustaud-Ratti V, Leroy V, Ahmed SNS, Ozenne V, Bronowicki JP, Larrey D, Tran A, Alric L, Nguyen-Khac E, Robertson MN, Hanna GJ, Brown D, Asante-Appiah E, Su FH, Hwang P, Hall JD, Guidoum A, Hagen K, Haber BA, Talwani R, Serfaty L

Liver Int.. 2019 Nov 25;:

The "six-and-twelve score" for TACE treatment: Does it really help us?

Bourlière M, Pénaranda G, Adhoute X, Bronowicki JP

J. Hepatol.. 2019 Sep 9;:

Emerging hepatitis E virus compared with hepatitis A virus: A new sanitary challenge.

Hartard C, Gantzer C, Bronowicki JP, Schvoerer E

Rev. Med. Virol.. 2019 Aug 27;:e2078

RNA editing blood biomarkers for predicting mood alterations in HCV patients.

Salvetat N, Van der Laan S, Vire B, Chimienti F, Cleophax S, Bronowicki JP, Doffoel M, Bourlière M, Schwan R, Lang JP, Pujol JF, Weissmann D

J. Neurovirol.. 2019 Jul 22;:

Pravastatin combination with Sorafenib does not improve survival in advanced Hepatocellular Carcinoma.

Jouve JL, Lecomte T, Bouché O, Barbier E, Akouz FK, Riachi G, Khac EN, Ollivier-Hourmand I, Debette-Gratien M, Faroux R, Villing AL, Vergniol J, Ramee JF, Bronowicki JP, Seitz JF, Legoux JL, Denis J, Manfredi S, Phelip JM,

J. Hepatol.. 2019 May 21;:

Vedolizumab therapy is ineffective for primary sclerosing cholangitis in patients with inflammatory bowel disease: A GETAID multicentre cohort study.

Caron B, Peyrin-Biroulet L, Pariente B, Bouhnik Y, Seksik P, Bouguen G, Caillo L, Laharie D, Carbonnel F, Altwegg R, Reenaers C, Serrero M, Trang-Poisson C, Nancey S, Filippi J, Abitbol V, Savoye G, Vuitton L, Viennot S, Fumery M, Reymond M, Bronowicki JP, Reimund JM, Amiot A,

J Crohns Colitis. 2019 May 6;:

Hepatocellular carcinoma macroscopic gross appearance on imaging: predictor of outcome after transarterial chemoembolization in a real-life multicenter French cohort.

Adhoute X, Pénaranda G, Raoul JL, Pietri O, Bronowicki JP, Castellani P, Perrier H, Monnet O, Bayle O, Oules V, Pol B, Beaurain P, Muller C, Cassagneau P, Bourlière M

Eur J Gastroenterol Hepatol. 2019 Apr 29;:

Doxorubicin-loaded nanoparticles for patients with advanced hepatocellular carcinoma after sorafenib treatment failure (RELIVE): a phase 3 randomised controlled trial.

Merle P, Blanc JF, Phelip JM, Pelletier G, Bronowicki JP, Touchefeu Y, Pageaux G, Gerolami R, Habersetzer F, Nguyen-Khac E, Casadei-Gardini A, Borbath I, Tran A, Wege H, Saad AS, Colombo M, Abergel A, Richou C, Waked I, Yee NS, Molé A, Attali P, Le Boulicaut J, Vasseur B,

Lancet Gastroenterol Hepatol. 2019 Apr 3;:

Safety and efficacy of the combination simeprevir-sofosbuvir in HCV genotype 1- and 4-mono-infected patients from the French ANRS CO22 hepather cohort.

Laurain A, Metivier S, Haour G, Larrey D, Dorival C, Hezode C, Zoulim F, Marcellin P, Bourliere M, Zarski JP, Thabut D, Alric L, Ganne-Carrie N, Cales P, Bronowicki JP, Riachi G, Geist C, Causse X, Abergel A, Chazouilleres O, Mathurin P, Guyader D, Samuel D, Tran A, Loustaud-Ratti V, Petrov-Sanchez V, Diallo A, Luzivika-Nzinga C, Fontaine H, Carrat F, Pol S,

BMC Infect. Dis.. 2019 Apr 2;19(1):300

Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy.

Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle-Bladou C, Dao T, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Sutton A, Audureau E, Roudot-Thoraval F, Nahon P,

Gastroenterology. 2019 Feb 13;:

Clinical outcomes in patients with chronic hepatitis C after direct-acting antiviral treatment: a prospective cohort study.

Carrat F, Fontaine H, Dorival C, Simony M, Diallo A, Hezode C, De Ledinghen V, Larrey D, Haour G, Bronowicki JP, Zoulim F, Asselah T, Marcellin P, Thabut D, Leroy V, Tran A, Habersetzer F, Samuel D, Guyader D, Chazouilleres O, Mathurin P, Metivier S, Alric L, Riachi G, Gournay J, Abergel A, Cales P, Ganne N, Loustaud-Ratti V, D'Alteroche L, Causse X, Geist C, Minello A, Rosa I, Gelu-Simeon M, Portal I, Raffi F, Bourliere M, Pol S,

Lancet. 2019 Feb 11;:

Dietary components modulate the risk of hepatocellular carcinoma in cirrhotic patients.

Rizk M, Guilloteau A, Mouillot T, Thiefin G, Bronowicki JP, Richou C, Doffoel M, Diab Assaf M, Hillon P, Cottet V

Nutr Res. 2019 Jan;61:82-94

Vaccination for influenza and pneumococcus in patients with gastrointestinal cancer or inflammatory bowel disease: A prospective cohort study of methods for improving coverage.

Sitte J, Frentiu E, Baumann C, Rousseau H, May T, Bronowicki JP, Peyrin-Biroulet L, Lopez A

Aliment. Pharmacol. Ther.. 2018 Nov 28;:

Impact of Cytomegalovirus Infection on the Outcome of Patients With Cirrhosis: A Preliminary Study.

Faivre M, Cottet V, Bour JB, Richou C, Valmary-Degano S, Thiefin G, Andreoletti L, Geist C, Schvoerer E, Malvé B, Habersetzer F, Fafi-Kremer S, Binquet C, Jouve JL, Bronowicki JP, Doffoel M, Hillon P, Herbein G, Monnet E, Di Martino V,

J. Clin. Gastroenterol.. 2018 Oct 31;:

Non-virological factors are drivers of Hepatocellular Carcinoma in virosuppressed Hepatitis B cirrhosis: results of ANRS CO12 CirVir cohort.

Brichler S, Nahon P, Zoulim F, Layese R, Bourcier V, Audureau E, Sutton A, Letouze E, Cagnot C, Marcellin P, Guyader D, Roulot D, Pol S, de Ledinghen V, Zarski JP, Calès P, Tran A, Peron JM, Mallat A, Riachi G, Grange JD, Blanc JF, Bacq Y, Ouzan D, Bronowicki JP, Mathurin P, Larrey D, Alric L, Attali P, Serfaty L, Pilette C, Bourlière M, Thabut D, Silvain C, Wartelle C, Zucman D, Christidis C, Roudot-Thoraval F, Ganne-Carrie N,

J. Viral Hepat.. 2018 Oct 31;:

Hepatocellular carcinoma and liver metastasis treated by hafnium oxide nanoparticles activated by stereotactic body radiation therapy.

Pracht M, Chajon E, de Baere T, Nguyen F, Bronowicki JP, Vendrely V, Baumann AS, Croisé-Laurent V, Rio E, Rolland Y, Le Sourd S, Gustin P, Perret C, Mornex F, Peiffert D, Merle P, Deutsch E

Ann. Oncol.. 2018 Oct;29 Suppl 8:viii240

Effects of Long-term Norfloxacin Therapy in Patients with Advanced Cirrhosis.

Moreau R, Elkrief L, Bureau C, Perarnau JM, Thévenot T, Saliba F, Louvet A, Nahon P, Lannes A, Anty R, Hillaire S, Pasquet B, Ozenne V, Rudler M, Ollivier-Hourmand I, Robic MA, d'Alteroche L, Di Martino V, Ripault MP, Pauwels A, Grangé JD, Carbonell N, Bronowicki JP, Payancé A, Rautou PE, Valla D, Gault N, Lebrec D,

Gastroenterology. 2018 Aug 22;:

Accuracy of calprotectin using the Quantum Blue® Reader for the diagnosis of spontaneous bacterial peritonitis in liver cirrhosis.

Weil D, Heurgue-Berlot A, Monnet E, Chassagne S, Cervoni JP, Feron T, Jaeger T, Grandvallet C, Muel E, Bronowicki JP, Thiefin G, Di Martino V, Bardonnet K, Thévenot T

Hepatol. Res.. 2018 Aug 7;:

Systematic screening for primary sclerosing cholangitis with magnetic resonance cholangiography in inflammatory bowel disease.

Belle A, Laurent V, Pouillon L, Baumann C, Orry X, Lopez A, Rousseau H, Bronowicki JP, Peyrin-Biroulet L

Dig Liver Dis. 2018 Jul 31;:

Computed tomographic perfusion with 160-mm coverage: comparative analysis of hepatocellular carcinoma treated by two transarterial chemoembolization courses relative to magnetic resonance imaging findings.

Bayle M, Clerc-Urmès I, Ayav A, Bronowicki JP, Petit I, Orry X, Laurent V

Abdom Radiol (NY). 2018 Jul 27;:

Incidence of Hepatocellular Carcinoma After Direct Antiviral Therapy for HCV in Patients With Cirrhosis Included in Surveillance Programs.

Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Roudot-Thoraval F, Audureau E,

Gastroenterology. 2018 Jul 18;:

A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis.

Corpechot C, Chazouillères O, Rousseau A, Le Gruyer A, Habersetzer F, Mathurin P, Goria O, Potier P, Minello A, Silvain C, Abergel A, Debette-Gratien M, Larrey D, Roux O, Bronowicki JP, Boursier J, de Ledinghen V, Heurgue-Berlot A, Nguyen-Khac E, Zoulim F, Ollivier-Hourmand I, Zarski JP, Nkontchou G, Lemoinne S, Humbert L, Rainteau D, Lefèvre G, de Chaisemartin L, Chollet-Martin S, Gaouar F, Admane FH, Simon T, Poupon R

N. Engl. J. Med.. 2018 06 7;378(23):2171-2181

Production of Elastin-Derived Peptides Contribute to the Development of Non-Alcoholic Steatohepatitis.

Romier B, Ivaldi C, Sartelet H, Heinz A, Schmelzer CEH, Garnotel R, Guillot A, Jonquet J, Bertin E, Guéant JL, Alberto JM, Bronowicki JP, Amoyel J, Hocine T, Duca L, Maurice P, Bennasroune A, Martiny L, Debelle L, Durlach V, Blaise S

Diabetes. 2018 May 25;:

Severe liver failure rather than cirrhosis is associated with mortality in patients with infectious endocarditis: a retrospective case-control study.

Allaire M, Cadranel JD, Bureau C, Zerkly S, Thévenot T, Garioud A, Cacoub P, Macaigne G, Alric L, Jouannaud V, Lison H, Chagneau-Derrode C, Pariente A, Pe Combining Acute Accent Laquier ACGAS, Bourlie Combining Grave Accent Re M, Causse X, Nousbaum JB, Dumortier JCAAR, Louvet A, Rosa-He Combining Acute Accent Zode I, Ganne-Carrie Combining Acute Accent N, Chentouh R, Sfaxi A, Gournay JCAAR, Blasco-Perrin HCAALCGAN, Antonini T, Spahr L, Bronowicki JP, Silvain C, Di Martino V, Grange JD, Denis J, Dupont K, Iaria P, Ollivier-Hourmand I, Dao T,

Eur J Gastroenterol Hepatol. 2018 May 3;:

Compliance With Hepatocellular Carcinoma Surveillance Guidelines Associated With Increased Lead-time Adjusted Survival of Patients With Compensated Viral Cirrhosis.

Costentin C, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Imbeaud S, Zucman-Rossi J, Audureau E, Roudot-Thoraval F, Nahon P,

Gastroenterology. 2018 May 2;:

Extra hepatic cancers are the leading cause of death in cirrhotic patients achieving HBV control or HCV eradication.

Allaire M, Nahon P, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Nguyen-Khac E, Bernard-Chabert B, Zucman D, Di Martino V, Sutton A, Letouzé E, Audureau E, Roudot-Thoraval F,

Hepatology. 2018 Apr 16;:

Molecular features of Hepatitis E Virus circulation in environmental and human samples.

Fenaux H, Chassaing M, Berger S, Jeulin H, Gentilhomme A, Bensenane M, Bronowicki JP, Gantzer C, Bertrand I, Schvoerer E

J. Clin. Virol.. 2018 Apr 5;103:63-70

Plasma mSEPT9: A Novel Circulating Cell-free DNA-Based Epigenetic Biomarker to Diagnose Hepatocellular Carcinoma.

Oussalah A, Rischer S, Bensenane M, Conroy G, Filhine-Tresarrieu P, Debard R, Forest-Tramoy D, Josse T, Reinicke D, Garcia M, Luc A, Baumann C, Ayav A, Laurent V, Hollenbach M, Ripoll C, Guéant-Rodriguez RM, Namour F, Zipprich A, Fleischhacker M, Bronowicki JP, Guéant JL

EBioMedicine. 2018 Apr;30:138-147

Prognostic value of viral eradication for major adverse cardiovascular events in hepatitis C cirrhotic patients.

Cacoub P, Nahon P, Layese R, Blaise L, Desbois AC, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Thabut D, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Zucman D, Di Martino V, Bagnis CI, Ziol M, Sutton A, Letouze E, Roudot-Thoraval F, Audureau E,

Am. Heart J.. 2018 Apr;198:4-17

Efficacy of daclatasvir-based quadruple therapy in nonresponder patients infected by hepatitis C virus genotype 4: the ANRS HC32 QUATTRO study.

Roulot D, Thibault V, Laforest C, Fontaine H, Bronowicki JP, Asselah T, Bourlière M, Canva V, Leroy V, Loustaud-Ratti V, Ouzan D, Zoulim F, Schischmanoff O, Rousseau C, Renault A, Petrov-Sanchez V, Diallo A, Bellissant E, Serfaty L,

Eur J Gastroenterol Hepatol. 2018 03;30(3):302-309

Efficacy and safety of selective internal radiotherapy with yttrium-90 resin microspheres compared with sorafenib in locally advanced and inoperable hepatocellular carcinoma (SARAH): an open-label randomised controlled phase 3 trial.

Vilgrain V, Pereira H, Assenat E, Guiu B, Ilonca AD, Pageaux GP, Sibert A, Bouattour M, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Castera L, Chatellier G,

Lancet Oncol.. 2017 Dec;18(12):1624-1636

The prognostic value of inflammation-based scores in advanced hepatocellular carcinoma patients prior to treatment with sorafenib.

Conroy G, Salleron J, Belle A, Bensenane M, Nani A, Ayav A, Peiffert D, Lopez A, Baumann C, Barraud H, Bronowicki JP

Oncotarget. 2017 Nov 10;8(56):95853-95864

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.

Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL,

Oncotarget. 2017 Sep;8(38):62842-62857

Microbiota in digestive cancers: our new partner?

Lopez A, Hansmannel F, Kokten T, Bronowicki JP, Melhem H, Sokol H, Peyrin-Biroulet L

Carcinogenesis. 2017 Aug;:

The variability of hepatitis B envelope is associated with HBs antigen persistence in either chronic or acute HBV genotype A infection.

Eschlimann M, Malvé B, Velay A, Fenaux H, Berger S, Frippiat JP, Zoulim F, Bensenane M, Bronowicki JP, Goehringer F, May T, Jeulin H, Schvoerer E

J. Clin. Virol.. 2017 Aug;94:115-122

Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

Bouattour M, Assenat E, Guiu B, Ilonca Alina D, Pageaux GP, Sibert A, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Pereira H, Castera L, Chatellier G, Vilgrain V,

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii150

LBA-001Efficacy, tolerability and impact on quality of life of selective internal radiation therapy (with yttrium-90 resin microspheres) or sorafenib in patients with locally advanced hepatocellular carcinoma: The SARAH trial.

Bouattour M, Assenat E, Guiu B, Ilonca Alina D, Pageaux GP, Sibert A, Lebtahi R, Allaham W, Barraud H, Laurent V, Mathias E, Bronowicki JP, Tasu JP, Perdrisot R, Silvain C, Gerolami R, Mundler O, Seitz JF, Vidal V, Aubé C, Oberti F, Couturier O, Brenot-Rossi I, Raoul JL, Sarran A, Costentin C, Itti E, Luciani A, Adam R, Lewin M, Samuel D, Ronot M, Dinut A, Pereira H, Castera L, Chatellier G, Vilgrain V,

Ann. Oncol.. 2017 Jun 1;28(suppl_3):

Updated overall survival (OS) analysis from the international, phase 3, randomized, placebo-controlled RESORCE trial of regorafenib for patients with hepatocellular carcinoma (HCC) who progressed on sorafenib treatment.

Bruix J, Merle P, Granito A, Huang YH, Bodoky G, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Qin S, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, LeBerre MA, Baumhauer A, Meinhardt G, Han G,

Ann. Oncol.. 2017 Jun;28 Suppl 3:iii140

Barcelona clinic liver cancer nomogram and others staging/scoring systems in a French hepatocellular carcinoma cohort.

Adhoute X, Pénaranda G, Raoul JL, Edeline J, Blanc JF, Pol B, Campanile M, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Le Treut YP, Bronowicki JP, Bourlière M

World J. Gastroenterol.. 2017 Apr;23(14):2545-2555

Effect on HBs antigen clearance of addition of pegylated interferon alfa-2a to nucleos(t)ide analogue therapy versus nucleos(t)ide analogue therapy alone in patients with HBe antigen-negative chronic hepatitis B and sustained undetectable plasma hepatitis

Bourlière M, Rabiega P, Ganne-Carrie N, Serfaty L, Marcellin P, Barthe Y, Thabut D, Guyader D, Hezode C, Picon M, Causse X, Leroy V, Bronowicki JP, Carrieri P, Riachi G, Rosa I, Attali P, Molina JM, Bacq Y, Tran A, Grangé JD, Zoulim F, Fontaine H, Alric L, Bertucci I, Bouvier-Alias M, Carrat F,

Lancet Gastroenterol Hepatol. 2017 Mar;2(3):177-188

25-OH vitamin D level has no impact on the efficacy of antiviral therapy in naïve genotype 1 HCV-infected patients.

Belle A, Gizard E, Conroy G, Lopez A, Bouvier-Alias M, Rouanet S, Peyrin-Biroulet L, Pawlotsky JM, Bronowicki JP

United European Gastroenterol J. 2017 Feb;5(1):69-75

Daclatasvir plus sofosbuvir, with or without ribavirin, for hepatitis C virus genotype 3 in a French early access programme.

Hézode C, Lebray P, De Ledinghen V, Zoulim F, Di Martino V, Boyer N, Larrey D, Botta-Fridlund D, Silvain C, Fontaine H, D'Alteroche L, Leroy V, Bourliere M, Hubert-Fouchard I, Guyader D, Rosa I, Nguyen-Khac E, Fedchuk L, Akremi R, Bennai Y, Filipovics A, Zhao Y, Bronowicki JP

Liver Int.. 2017 Feb;:

NIACE score for hepatocellular carcinoma patients treated by surgery or transarterial chemoembolization.

Adhoute X, Pénaranda G, Raoul JL, Bollon E, Pol B, Letreut YP, Perrier H, Bayle O, Monnet O, Beaurain P, Muller C, Hardwigsen J, Lefolgoc G, Castellani P, Bronowicki JP, Bourlière M

Eur J Gastroenterol Hepatol. 2017 Feb;:

Eradication of Hepatitis C Virus Infection in Patients With Cirrhosis Reduces Risk of Liver and Non-Liver Complications.

Nahon P, Bourcier V, Layese R, Audureau E, Cagnot C, Marcellin P, Guyader D, Fontaine H, Larrey D, De Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Leroy V, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Dharancy S, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Thibaut V, Salmon D, Ziol M, Sutton A, Pol S, Roudot-Thoraval F,

Gastroenterology. 2017 Jan;152(1):142-156.e2

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.

Bruix J, Qin S, Merle P, Granito A, Huang YH, Bodoky G, Pracht M, Yokosuka O, Rosmorduc O, Breder V, Gerolami R, Masi G, Ross PJ, Song T, Bronowicki JP, Ollivier-Hourmand I, Kudo M, Cheng AL, Llovet JM, Finn RS, LeBerre MA, Baumhauer A, Meinhardt G, Han G,

Lancet. 2017 01;389(10064):56-66

Safety and efficacy of daclatasvir-sofosbuvir in HCV genotype 1-mono-infected patients.

Pol S, Bourliere M, Lucier S, Hezode C, Dorival C, Larrey D, Bronowicki JP, Ledinghen VD, Zoulim F, Tran A, Metivier S, Zarski JP, Samuel D, Guyader D, Marcellin P, Minello A, Alric L, Thabut D, Chazouilleres O, Riachi G, Bourcier V, Mathurin P, Loustaud-Ratti V, D'Alteroche L, Fouchard-Hubert I, Habersetzer F, Causse X, Geist C, Rosa I, Gournay J, Saillard E, Billaud E, Petrov-Sanchez V, Diallo A, Fontaine H, Carrat F,

J. Hepatol.. 2017 Jan;66(1):39-47

Safety and efficacy of intra-arterial hepatic chemotherapy with doxorubicin-loaded nanoparticles in hepatocellular carcinoma.

Merle P, Camus P, Abergel A, Pageaux GP, Masliah C, Bronowicki JP, Zarski JP, Pelletier G, Bouattour M, Farloux L, Dorval E, Verset G, Si-Ahmed SN, Doffoel M, Couzigou P, Taieb J, Vasseur B, Attali P

ESMO Open. 2017 ;2(4):e000238

Efficacy and Safety of Ledipasvir/Sofosbuvir With and Without Ribavirin in Patients With Chronic HCV Genotype 1 Infection Receiving Opioid Substitution Therapy: Analysis of Phase 3 ION Trials.

Grebely J, Mauss S, Brown A, Bronowicki JP, Puoti M, Wyles D, Natha M, Zhu Y, Yang J, Kreter B, Brainard DM, Yun C, Carr V, Dore GJ

Clin. Infect. Dis.. 2016 Dec;63(11):1405-1411

Observational registry of sorafenib use in clinical practice across Child-Pugh subgroups: The GIDEON study.

Marrero JA, Kudo M, Venook AP, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JH, de Guevara LL, Papandreou C, Takayama T, Sanyal AJ, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R

J. Hepatol.. 2016 Dec;65(6):1140-1147

Foetal programming by methyl donor deficiency produces steato-hepatitis in rats exposed to high fat diet.

Bison A, Marchal-Bressenot A, Li Z, Elamouri I, Feigerlova E, Peng L, Houlgatte R, Beck B, Pourié G, Alberto JM, Umoret R, Conroy G, Bronowicki JP, Guéant JL, Guéant-Rodriguez RM

Sci Rep. 2016 Nov;6:37207

Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir).

Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, Pol S, Larrey D, de Lédinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Riachi G, Calès P, Péron JM, Alric L, Bourlière M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grangé JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Zucman D, Di Martino V, Trinchet JC, Nahon P, Roudot-Thoraval F,

Hepatology. 2016 Oct;64(4):1136-47

BRIP1 coding variants are associated with a high risk of hepatocellular carcinoma occurrence in patients with HCV- or HBV-related liver disease.

Oussalah A, Avogbe PH, Guyot E, Chery C, Guéant-Rodriguez RM, Ganne-Carrié N, Cobat A, Moradpour D, Nalpas B, Negro F, Poynard T, Pol S, Bochud PY, Abel L, Jeulin H, Schvoerer E, Chabi N, Amouzou E, Sanni A, Barraud H, Rouyer P, Josse T, Goffinet L, Jouve JL, Minello A, Bonithon-Kopp C, Thiefin G, Di Martino V, Doffoël M, Richou C, Raab JJ, Hillon P, Bronowicki JP, Guéant JL, Study Group FT

Oncotarget. 2016 Aug;:

Regional differences in sorafenib-treated patients with hepatocellular carcinoma: GIDEON observational study.

Kudo M, Lencioni R, Marrero JA, Venook AP, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Ye SL

Liver Int.. 2016 Aug;36(8):1196-205

Characterization of hepatitis B virus surface antigen variability and impact on HBs antigen clearance under nucleos(t)ide analogue therapy.

Velay A, Jeulin H, Eschlimann M, Malvé B, Goehringer F, Bensenane M, Frippiat JP, Abraham P, Ismail AM, Murray JM, Combet C, Zoulim F, Bronowicki JP, Schvoerer E

J. Viral Hepat.. 2016 May;23(5):387-98

Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: A randomized phase III study (ALLY-3+).

Leroy V, Angus P, Bronowicki JP, Dore GJ, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ

Hepatology. 2016 May;63(5):1430-41

TACE Treatment in Patients with Sorafenib-treated Unresectable Hepatocellular Carcinoma in Clinical Practice: Final Analysis of GIDEON.

Geschwind JF, Kudo M, Marrero JA, Venook AP, Chen XP, Bronowicki JP, Dagher L, Furuse J, Ladrón de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Ye SL, Yoon SK, Nakajima K, Lehr R, Heldner S, Lencioni R

Radiology. 2016 May;279(2):630-40

Prognosis of advanced hepatocellular carcinoma: a new stratification of Barcelona Clinic Liver Cancer stage C: results from a French multicenter study.

Adhoute X, Pénaranda G, Raoul JL, Blanc JF, Edeline J, Conroy G, Perrier H, Pol B, Bayle O, Monnet O, Beaurain P, Muller C, Castellani P, Bronowicki JP, Bourlière M

Eur J Gastroenterol Hepatol. 2016 Apr;28(4):433-40

[Which place for point-of-care screening tests in the diagnosis of hepatitis C infection among drug users?].

Lacroix N, Barraud H, Gillet C, Di Patrizio P, Bronowicki JP, Schwan R, Laprévote V

Presse Med. 2016 Apr;45(4 Pt 1):431-7

CT imaging findings in patients with advanced hepatocellular carcinoma treated with sorafenib: Alternative response criteria (Choi, European Association for the Study of the Liver, and modified Response Evaluation Criteria in Solid Tumor (mRECIST)) versus

Gavanier M, Ayav A, Sellal C, Orry X, Claudon M, Bronowicki JP, Laurent V

Eur J Radiol. 2016 Jan;85(1):103-12

Bacterial infection in compensated viral cirrhosis impairs 5-year survival (ANRS CO12 CirVir prospective cohort).

Nahon P, Lescat M, Layese R, Bourcier V, Talmat N, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Ledinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Cales P, Peron JM, Alric L, Bourliere M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grange JD, Attali P, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Bernard-Chabert B, Hillaire S, Di Martino V, Trinchet JC, Moreau R, Roudot-Thoraval F

Gut. 2015 Oct 28. pii: gutjnl-2015-310275

Daclatasvir plus simeprevir with or without ribavirin for the treatment of chronic hepatitis C virus genotype 1 infection.

Zeuzem S, Hezode C, Bronowicki JP, Loustaud-Ratti V, Gea F, Buti M, Olveira A, Banyai T, Al-Assi MT, Petersen J, Thabut D, Gadano A, Pruitt R, Makara M, Bourliere M, Pol S, Beumont-Mauviel M, Ouwerkerk-Mahadevan S, Picchio G, Bifano M, McPhee F, Boparai N, Cheung K, Hughes EA, Noviello S

J Hepatol. 2015 Oct 7. pii: S0168-8278(15)00672-8

Complications and competing risks of death in compensated viral cirrhosis (ANRS CO12 CirVir prospective cohort).

Trinchet JC, Bourcier V, Chaffaut C, Ait Ahmed M, Allam S, Marcellin P, Guyader D, Pol S, Larrey D, De Ledinghen V, Ouzan D, Zoulim F, Roulot D, Tran A, Bronowicki JP, Zarski JP, Goria O, Cales P, Peron JM, Alric L, Bourliere M, Mathurin P, Blanc JF, Abergel A, Serfaty L, Mallat A, Grange JD, Buffet C, Bacq Y, Wartelle C, Dao T, Benhamou Y, Pilette C, Silvain C, Christidis C, Capron D, Thiefin G, Hillaire S, Di Martino V, Nahon P, Chevret S

Hepatology. 2015 Sep;62(3):737-50

Ideal oral combinations to eradicate HCV: The role of ribavirin.

Hezode C, Bronowicki JP

J Hepatol. 2015 Sep 26. pii: S0168-8278(15)00627-3

Impact of immunosuppressive therapy on hepatitis B vaccination in inflammatory bowel diseases.

Belle A, Baumann C, Bigard MA, Zallot C, Gizard E, Gueant JL, Bronowicki JP, Peyrin-Biroulet L

Eur J Gastroenterol Hepatol. 2015 Aug;27(8):877-81

Impact of sorafenib dosing on outcome from the European patient subset of the GIDEON study.

Daniele B, Croitoru A, Papandreou C, Bronowicki JP, Mathurin P, Serejo F, Stal P, Turnes J, Ratziu V, Bodoky G

Future Oncol. 2015 Jul 9:1-10.

Plasma apolipoprotein H limits HCV replication and associates with response to NS3 protease inhibitors-based therapy.

Sultanik P, Mallet V, Lagaye S, Casrouge A, Dorival C, Barthe Y, Fontaine H, Hézode C, Mottez E, Bronowicki JP, Carrat F, Theodorou I, Abel L, Gayat E, Fontanet A, Pol S, Albert ML,

Liver Int.. 2015 Jul;35(7):1833-44

The CUPIC algorithm: an accurate model for the prediction of sustained viral response under telaprevir or boceprevir triple therapy in cirrhotic patients.

Boursier J, Ducancelle A, Vergniol J, Veillon P, Moal V, Dufour C, Bronowicki JP, Larrey D, Hezode C, Zoulim F, Fontaine H, Canva V, Poynard T, Allam S, De Ledinghen V

J Viral Hepat. 2015 Jul 27

Exome-Wide Association Study Identifies New Low-Frequency and Rare UGT1A1 Coding Variants and UGT1A6 Coding Variants Influencing Serum Bilirubin in Elderly Subjects: A Strobe Compliant Article.

Oussalah A, Bosco P, Anello G, Spada R, Gueant-Rodriguez RM, Chery C, Rouyer P, Josse T, Romano A, Elia M, Bronowicki JP, Gueant JL

Medicine (Baltimore). 2015 Jun;94(22):e925

The Impact of Ledipasvir/Sofosbuvir on Patient-Reported Outcomes in Cirrhotic Patients with Chronic Hepatitis C: The SIRIUS Study.

Younossi ZM, Stepanova M, Pol S, Bronowicki JP, Carrieri MP, Bourliere M

Liver Int. 2015 Jun 9

Fixed-dose combination therapy with daclatasvir, asunaprevir, and beclabuvir for noncirrhotic patients with HCV genotype 1 infection.

Poordad F, Sievert W, Mollison L, Bennett M, Tse E, Brau N, Levin J, Sepe T, Lee SS, Angus P, Conway B, Pol S, Boyer N, Bronowicki JP, Jacobson I, Muir AJ, Reddy KR, Tam E, Ortiz-Lasanta G, de Ledinghen V, Sulkowski M, Boparai N, McPhee F, Hughes E, Swenson ES, Yin PD

JAMA. 2015 May 5;313(17):1728-35

High cure rate with 24 weeks of daclatasvir-based quadruple therapy in treatment-experienced null-responder HIV/HCV genotype 1/4 co-infected patients: the ANRS HC 30 QUADRIH study.

Piroth L, Paniez H, Taburet AM, Vincent C, Rosenthal E, Lacombe K, Billaud E, Rey D, Zucman D, Bailly F, Bronowicki JP, Simony M, Diallo A, Izopet J, Aboulker JP, Meyer L, Molina JM

Clin Infect Dis. 2015 May 14. pii: civ381.

Stereotactic body radiation therapy as an ablative treatment for inoperable hepatocellular carcinoma.

Huertas A, Baumann AS, Saunier-Kubs F, Salleron J, Oldrini G, Croise-Laurent V, Barraud H, Ayav A, Bronowicki JP, Peiffert D

Radiother Oncol. 2015 May;115(2):211-6

Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS).

Bourliere M, Bronowicki JP, de Ledinghen V, Hezode C, Zoulim F, Mathurin P, Tran A, Larrey DG, Ratziu V, Alric L, Hyland RH, Jiang D, Doehle B, Pang PS, Symonds WT, Subramanian GM, McHutchison JG, Marcellin P, Habersetzer F, Guyader D, Grange JD, Loustaud-Ratti V, Serfaty L, Metivier S, Leroy V, Abergel A, Pol S

Lancet Infect Dis. 2015 Apr;15(4):397-404

Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous

Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B

Lancet. 2015 Mar 21;385(9973):1075-86

Efficacy and safety of faldaprevir, deleobuvir, and ribavirin in treatment-naive patients with chronic hepatitis C virus infection and advanced liver fibrosis or cirrhosis.

Zeuzem S, Soriano V, Asselah T, Gane EJ, Bronowicki JP, Angus P, Lohse AW, Stickel F, Mullhaupt B, Roberts S, Schuchmann M, Manns M, Bourliere M, Buti M, Stern JO, Gallivan JP, Voss F, Sabo JP, Bocher W, Mensa FJ

Antimicrob Agents Chemother. 2015 Feb;59(2):1282-91

Usefulness of the HKLC vs. the BCLC staging system in a European HCC cohort.

Adhoute X, Penaranda G, Bronowicki JP, Raoul JL

J Hepatol. 2015 Feb;62(2):492-3

A Model-Based Illustrative Exploratory Approach to Optimize the Dosing of Peg-IFN/RBV in Cirrhotic Hepatitis C Patients Treated With Triple Therapy.

Laouénan C, Guedj J, Peytavin G, Nguyen TT, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hézode C, Carrat F, Nicot F, Marcellin P, Mentré F

CPT Pharmacometrics Syst Pharmacol. 2015 Jan;4(1):e00008

Early virological assessment during telaprevir- or boceprevir-based triple therapy in hepatitis C cirrhotic patients who failed a previous interferon based regimen - The ANRS CO20-CUPIC study.

Bailly F, Virlogeux V, Dufour C, Pradat P, Hezode C, Larrey D, Alric L, Samuel D, Bourliere M, Metivier S, Zarski JP, Fontaine H, Loustaud-Ratti V, Serfaty L, Bronowicki JP, Carrat F, Zoulim F

Clin Res Hepatol Gastroenterol. 2015 Jan 27. pii: S2210-7401(15)00002-9

Impact of IL28B, APOH and ITPA Polymorphisms on Efficacy and Safety of TVR- or BOC-Based Triple Therapy in Treatment-Experienced HCV-1 Patients with Compensated Cirrhosis from the ANRS CO20-CUPIC Study.

About F, Oudot-Mellakh T, Niay J, Rabiéga P, Pedergnana V, Duffy D, Sultanik P, Cagnot C, Carrat F, Marcellin P, Zoulim F, Larrey D, Hézode C, Fontaine H, Bronowicki JP, Pol S, Albert ML, Theodorou I, Cobat A, Abel L,

PLoS ONE. 2015 ;10(12):e0145105

ITPA Genotypes Predict Anemia but Do Not Affect Virological Response with Interferon-Free Faldaprevir, Deleobuvir, and Ribavirin for HCV Infection.

Asselah T, Zeuzem S, Soriano V, Bronowicki JP, Lohse AW, Müllhaupt B, Schuchmann M, Bourlière M, Buti M, Roberts SK, Gane EJ, Stern JO, Voss F, Baum P, Gallivan JP, Böcher WO, Mensa FJ

PLoS ONE. 2015 ;10(12):e0144004

Prevalence of renal abnormalities in chronic HBV infection: the HARPE study.

Amet S, Bronowicki JP, Thabut D, Zoulim F, Bourliere M, Mathurin P, de Ledinghen V, Benhamou Y, Larrey DG, Janus N, Deray G, Launay-Vacher V, Pol S

Liver Int. 2015 Jan;35(1):148-55

Randomized trial of asunaprevir plus peginterferon alfa and ribavirin for previously untreated genotype 1 or 4 chronic hepatitis C.

Bronowicki JP, Ratziu V, Gadano A, Thuluvath PJ, Bessone F, Martorell CT, Pol S, Terg R, Younes Z, He B, Eley T, Cohen D, Yu F, Hernandez D, McPhee F, Mendez P, Hughes E

J Hepatol. 2014 Dec;61(6):1220-7

All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study.

Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S

Lancet. 2014 Nov 1;384(9954):1597-605

Retreatment with TACE: the ABCR SCORE, an aid to the decision-making process.

Adhoute X, Penaranda G, Naude S, Raoul JL, Perrier H, Bayle O, Monnet O, Beaurain P, Bazin C, Pol B, Le Folgoc G, Castellani P, Bronowicki JP, Bourliere M

J Hepatol. 2014 Nov 21. pii: S0168-8278(14)00858-7

Using pharmacokinetic and viral kinetic modeling to estimate the antiviral effectiveness of telaprevir, boceprevir, and pegylated interferon during triple therapy in treatment-experienced hepatitis C virus-infected cirrhotic patients.

Laouenan C, Marcellin P, Lapalus M, Khelifa-Mouri F, Boyer N, Zoulim F, Serfaty L, Bronowicki JP, Martinot-Peignoux M, Lada O, Asselah T, Dorival C, Hezode C, Carrat F, Nicot F, Peytavin G, Mentre F, Guedj J

Antimicrob Agents Chemother. 2014 Sep;58(9):5332-41

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.

Hezode C, Fontaine H, Dorival C, Zoulim F, Larrey D, Canva V, De Ledinghen V, Poynard T, Samuel D, Bourliere M, Alric L, Raabe JJ, Zarski JP, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Chazouilleres O, Abergel A, Guyader D, Metivier S, Tran A, Di Martino V, Causse X, Dao T, Lucidarme D, Portal I, Cacoub P, Gournay J, Grando-Lemaire V, Hillon P, Attali P, Fontanges T, Rosa I, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP

Gastroenterology. 2014 Jul;147(1):132-142.e4

Systematic review: The epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease.

Gizard E, Ford AC, Bronowicki JP, Peyrin-Biroulet L

Aliment Pharmacol Ther. 2014 Jul;40(1):3-15

Simeprevir with peginterferon and ribavirin leads to high rates of SVR in patients with HCV genotype 1 who relapsed after previous therapy: a phase 3 trial.

Forns X, Lawitz E, Zeuzem S, Gane E, Bronowicki JP, Andreone P, Horban A, Brown A, Peeters M, Lenz O, Ouwerkerk-Mahadevan S, Scott J, De La Rosa G, Kalmeijer R, Sinha R, Beumont-Mauviel M

Gastroenterology. 2014 Jun;146(7):1669-79.e3

Boceprevir plus peginterferon alpha-2b/ribavirin in chronic hepatitis C genotype 1: impact of baseline viral load on sustained virologic response.

Gordon SC, Reddy KR, Jacobson IM, Poordad F, Bronowicki JP, Bacon B, Buti M, Hu KQ, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Lawitz EJ

J Clin Gastroenterol. 2014 May-Jun;48(5):435-43

Overall safety profile of boceprevir plus peginterferon alfa-2b and ribavirin in patients with chronic hepatitis C genotype 1: a combined analysis of 3 phase 2/3 clinical trials.

Manns MP, McCone J Jr, Davis MN, Rossaro L, Schiff E, Shiffman ML, Bacon B, Bourliere M, Sulkowski MS, Bruno S, Balart L, Bronowicki JP, Kwo P, Poordad F, Felizarta F, Reddy KR, Helmond FA, Sings HL, Pedicone LD, Burroughs M, Brass CA, Albrecht JK, Vierling JM

Liver Int. 2014 May;34(5):707-19

Clinical allergy. Managing generalized interferon-induced eruptions and the effectiveness of desensitization.

Poreaux C, Bronowicki JP, Debouverie M, Schmutz JL, Waton J, Barbaud A

Clin Exp Allergy. 2014;44(5):756-64

GIDEON (Global Investigation of therapeutic DEcisions in hepatocellular carcinoma and Of its treatment with sorafeNib): second interim analysis.

Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladron de Guevara L, Papandreou C, Takayama T, Yoon SK, Nakajima K, Lehr R, Heldner S, Sanyal AJ

Int J Clin Pract. 2013 Nov 28

Antiviral effect, safety, and pharmacokinetics of five-day oral administration of Deleobuvir (BI 207127), an investigational hepatitis C virus RNA polymerase inhibitor, in patients with chronic hepatitis C.

Larrey D, Lohse AW, Trepo C, Bronowicki JP, Arasteh K, Bourliere M, Calleja JL, Stern JO, Nehmiz G, Abdallah N, Berger KL, Marquis M, Steffgen J, Kukolj G

Antimicrob Agents Chemother. 2013 Oct;57(10):4727-35

Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890.

Hezode C, Fontaine H, Dorival C, Larrey D, Zoulim F, Canva V, de Ledinghen V, Poynard T, Samuel D, Bourliere M, Zarski JP, Raabe JJ, Alric L, Marcellin P, Riachi G, Bernard PH, Loustaud-Ratti V, Metivier S, Tran A, Serfaty L, Abergel A, Causse X, Di Martino V, Guyader D, Lucidarme D, Grando-Lemaire V, Hillon P, Feray C, Dao T, Cacoub P, Rosa I, Attali P, Petrov-Sanchez V, Barthe Y, Pawlotsky JM, Pol S, Carrat F, Bronowicki JP

J Hepatol. 2013 Sep;59(3):434-41

Faldaprevir and deleobuvir for HCV genotype 1 infection.

Zeuzem S, Soriano V, Asselah T, Bronowicki JP, Lohse AW, Mullhaupt B, Schuchmann M, Bourliere M, Buti M, Roberts SK, Gane EJ, Stern JO, Vinisko R, Kukolj G, Gallivan JP, Bocher WO, Mensa FJ

N Engl J Med. 2013 Aug 15;369(7):630-9

Adherence to assigned dosing regimen and sustained virological response among chronic hepatitis C genotype 1 patients treated with boceprevir plus peginterferon alfa-2b/ribavirin.

Gordon SC, Yoshida EM, Lawitz EJ, Bacon BR, Sulkowski MS, Davis M, Poordad F, Bronowicki JP, Esteban R, Sniukiene V, Burroughs MH, Deng W, Dutko FJ, Brass CA, Albrecht JK, Rajender Reddy K

Aliment Pharmacol Ther. 2013 Jul;38(1):16-27

Anemia during treatment with peginterferon Alfa-2b/ribavirin and boceprevir: Analysis from the serine protease inhibitor therapy 2 (SPRINT-2) trial.

Sulkowski MS, Poordad F, Manns MP, Bronowicki JP, Rajender Reddy K, Harrison SA, Afdhal NH, Sings HL, Pedicone LD, Koury KJ, Sniukiene V, Burroughs MH, Albrecht JK, Brass CA, Jacobson IM

Hepatology. 2013 Mar;57(3):974-84

Interferon-gamma with peginterferon alpha-2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI).

Couzigou P, Perusat S, Bourliere M, Trimoulet P, Poynard T, Leroy V, Marcellin P, Foucher J, Bronowicki JP, Chene G

J Gastroenterol Hepatol. 2013 Feb;28(2):329-34

[Curative treatment of hepatocellular carcinoma].

Barraud H, Bronowicki JP

Rev Prat. 2013 Feb;63(2):229-33.

Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study.

Ferrante SA, Chhatwal J, Brass CA, El Khoury AC, Poordad F, Bronowicki JP, Elbasha EH

BMC Infect Dis. 2013 Apr 27;13:190

Faldaprevir (BI 201335), deleobuvir (BI 207127) and ribavirin oral therapy for treatment-naive HCV genotype 1: SOUND-C1 final results.

Zeuzem S, Asselah T, Angus P, Zarski JP, Larrey D, Mullhaupt B, Gane E, Schuchmann M, Lohse AW, Pol S, Bronowicki JP, Roberts S, Arasteh K, Zoulim F, Heim M, Stern JO, Nehmiz G, Kukolj G, Bocher WO, Mensa FJ

Antivir Ther. 2013;18(8):1015-9

Randomized study of asunaprevir plus pegylated interferon-alpha and ribavirin for previously untreated genotype 1 chronic hepatitis C.

Bronowicki JP, Pol S, Thuluvath PJ, Larrey D, Martorell CT, Rustgi VK, Morris DW, Younes Z, Fried MW, Bourliere M, Hezode C, Reddy KR, Massoud O, Abrams GA, Ratziu V, He B, Eley T, Ahmad A, Cohen D, Hindes R, McPhee F, Reilly B, Mendez P, Hughes E

Antivir Ther. 2013;18(7):885-93

Daclatasvir for previously untreated chronic hepatitis C genotype-1 infection: a randomised, parallel-group, double-blind, placebo-controlled, dose-finding, phase 2a trial.

Pol S, Ghalib RH, Rustgi VK, Martorell C, Everson GT, Tatum HA, Hezode C, Lim JK, Bronowicki JP, Abrams GA, Brau N, Morris DW, Thuluvath PJ, Reindollar RW, Yin PD, Diva U, Hindes R, McPhee F, Hernandez D, Wind-Rotolo M, Hughes EA, Schnittman S

Lancet Infect Dis. 2012 Sep;12(9):671-7

Factors that predict response of patients with hepatitis C virus infection to boceprevir.

Poordad F, Bronowicki JP, Gordon SC, Zeuzem S, Jacobson IM, Sulkowski MS, Poynard T, Morgan TR, Molony C, Pedicone LD, Sings HL, Burroughs MH, Sniukiene V, Boparai N, Goteti VS, Brass CA, Albrecht JK, Bacon BR

Gastroenterology. 2012 Sep;143(3):608-18.e1-5

Methyl donor deficiency impairs fatty acid oxidation through PGC-1α hypomethylation and decreased ER-α, ERR-α, and HNF-4α in the rat liver.

Pooya S, Blaise S, Moreno Garcia M, Giudicelli J, Alberto JM, Guéant-Rodriguez RM, Jeannesson E, Gueguen N, Bressenot A, Nicolas B, Malthiery Y, Daval JL, Peyrin-Biroulet L, Bronowicki JP, Guéant JL

J. Hepatol.. 2012 Aug;57(2):344-51

Refinement of stopping rules during treatment of hepatitis C genotype 1 infection with boceprevir and peginterferon/ribavirin.

Jacobson IM, Marcellin P, Zeuzem S, Sulkowski MS, Esteban R, Poordad F, Bruno S, Burroughs MH, Pedicone LD, Boparai N, Deng W, DiNubile MJ, Gottesdiener KM, Brass CA, Albrecht JK, Bronowicki JP

Hepatology. 2012 Aug;56(2):567-75

First interim analysis of the GIDEON (Global Investigation of therapeutic decisions in hepatocellular carcinoma and of its treatment with sorafeNib) non-interventional study.

Lencioni R, Kudo M, Ye SL, Bronowicki JP, Chen XP, Dagher L, Furuse J, Geschwind JF, Ladron de Guevara L, Papandreou C, Sanyal AJ, Takayama T, Yoon SK, Nakajima K, Cihon F, Heldner S, Marrero JA

Int J Clin Pract. 2012 Jul;66(7):675-83

Fumonisin FB1 treatment acts synergistically with methyl donor deficiency during rat pregnancy to produce alterations of H3- and H4-histone methylation patterns in fetuses.

Pellanda H, Forges T, Bressenot A, Chango A, Bronowicki JP, Gueant JL, Namour F

Mol Nutr Food Res. 2012 Jun;56(6):976-85

A splicing variant leads to complete loss of function of betaine-homocysteine methyltransferase (BHMT) gene in hepatocellular carcinoma.

Pellanda H, Namour F, Fofou-Caillierez M, Bressenot A, Alberto JM, Chery C, Ayav A, Bronowicki JP, Gueant JL, Forges T

Int J Biochem Cell Biol. 2012 Feb;44(2):385-92

Helicobacter pylori serologic status has no influence on the association between fucosyltransferase 2 polymorphism (FUT2 461 G->A) and vitamin B-12 in Europe and West Africa.

Oussalah A, Besseau C, Chery C, Jeannesson E, Gueant-Rodriguez RM, Anello G, Bosco P, Elia M, Romano A, Bronowicki JP, Gerard P, Paoli J, Avogbe PH, Chabi N, Sanni A, Amouzou E, Peyrin-Biroulet L, Gueant JL

Am J Clin Nutr. 2012 Feb;95(2):514-21

Longitudinal liver stiffness assessment in patients with chronic hepatitis C undergoing antiviral therapy.

Martinez SM, Foucher J, Combis JM, Metivier S, Brunetto M, Capron D, Bourliere M, Bronowicki JP, Dao T, Maynard-Muet M, Lucidarme D, Merrouche W, Forns X, de Ledinghen V

PLoS One. 2012;7(10):e47715

Ultrasonographic surveillance of hepatocellular carcinoma in cirrhosis: a randomized trial comparing 3- and 6-month periodicities.

Trinchet JC, Chaffaut C, Bourcier V, Degos F, Henrion J, Fontaine H, Roulot D, Mallat A, Hillaire S, Cales P, Ollivier I, Vinel JP, Mathurin P, Bronowicki JP, Vilgrain V, N'Kontchou G, Beaugrand M, Chevret S

Hepatology. 2011 Dec;54(6):1987-97

A poxvirus vaccine is safe, induces T-cell responses, and decreases viral load in patients with chronic hepatitis C.

Habersetzer F, Honnet G, Bain C, Maynard-Muet M, Leroy V, Zarski JP, Feray C, Baumert TF, Bronowicki JP, Doffoel M, Trepo C, Agathon D, Toh ML, Baudin M, Bonnefoy JY, Limacher JM, Inchauspe G

Gastroenterology. 2011 Sep;141(3):890-899.e1-4

Telaprevir alone or with peginterferon and ribavirin reduces HCV RNA in patients with chronic genotype 2 but not genotype 3 infections.

Foster GR, Hezode C, Bronowicki JP, Carosi G, Weiland O, Verlinden L, van Heeswijk R, van Baelen B, Picchio G, Beumont M

Gastroenterology. 2011 Sep;141(3):881-889.e1

High-dose pegylated interferon-alpha and ribavirin in nonresponder hepatitis C patients and relationship with IL-28B genotype (SYREN trial).

Chevaliez S, Hezode C, Soulier A, Costes B, Bouvier-Alias M, Rouanet S, Foucher J, Bronowicki JP, Tran A, Rosa I, Mathurin P, Alric L, Leroy V, Couzigou P, Mallat A, Charaf-Eddine M, Babany G, Pawlotsky JM

Gastroenterology. 2011 Jul;141(1):119-27

Crystal-storing histiocytosis in ascites from a patient with IgM kappa lymphoplasmacytic lymphoma.

Lesesve JF, Bronowicki JP, Galed-Placed I

Cytopathology. 2011 Jun;22(3):207-8

[Wilson's disease in an adult].

Mercier-Jacquier M, Bronowicki JP, Raabe JJ, Jacquier A, Kaminsky P

Rev Med Interne. 2011 Jun;32(6):341-6

[Cirrhosis and complications].

Barraud H, Bronowicki JP

Rev Prat. 2011 May;61(5):709-16.

Boceprevir for untreated chronic HCV genotype 1 infection.

Poordad F, McCone J Jr, Bacon BR, Bruno S, Manns MP, Sulkowski MS, Jacobson IM, Reddy KR, Goodman ZD, Boparai N, DiNubile MJ, Sniukiene V, Brass CA, Albrecht JK, Bronowicki JP

N Engl J Med. 2011 Mar 31;364(13):1195-206.

Reactivation of viral hepatitis in immunosuppressed patients: an ounce of prevention is worth a pound of cure.

Belle A, Bronowicki JP, Peyrin-Biroulet L

Gastroenterology. 2011 Jan;140(1):360-2; discussion 362-3

[Risk of HBV reactivation under chemotherapy and immunosuppressants].

Belle A, Bronowicki JP

Rev Prat. 2011 Jan;61(1):52-4.

Neutralizing antibodies to interferon-alpha and circulating interferon in patients with chronic hepatitis C non-responding to pegylated interferon plus ribavirin re-treated by pegylated interferon-alpha-2a and ribavirin (ANRS HC16 GAMMATRI substudy).

Halfon P, Perusat S, Bourliere M, Bronowicki JP, Trimoulet P, Benhamou Y, Leroy V, Marcellin P, Foucher J, Penaranda G, Chene G, Couzigou P

J Med Virol. 2010 Dec;82(12):2027-31.

Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin.

Diago M, Shiffman ML, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, Tietz A, Nelson DR

Hepatology. 2010 Jun;51(6):1897-903.

Prevalence of hepatitis B and C and risk factors for nonvaccination in inflammatory bowel disease patients in Northeast France.

Chevaux JB, Nani A, Oussalah A, Venard V, Bensenane M, Belle A, Gueant JL, Bigard MA, Bronowicki JP, Peyrin-Biroulet L

Inflamm Bowel Dis. 2010 Jun;16(6):916-24.

Current approaches to the treatment of early hepatocellular carcinoma.

Ye SL, Takayama T, Geschwind J, Marrero JA, Bronowicki JP

Oncologist. 2010;15 Suppl 4:34-41.

The challenge of prognosis and staging for hepatocellular carcinoma.

Marrero JA, Kudo M, Bronowicki JP

Oncologist. 2010;15 Suppl 4:23-33.

Inflammatory bowel disease and hepatitis B and C.

Chevaux JB, Bigard MA, Bensenane M, Oussalah A, Jarlot S, Belle A, Nani A, Bronowicki JP, Peyrin-Biroulet L

Gastroenterol Clin Biol. 2009 Dec;33(12):1082-93

Metformin plus pentoxifylline versus prescriptive diet in non-alcoholic steatohepatitis (NASH): a randomized controlled pilot trial.

Sturm N, Bronowicki JP, Maynard-Muet M, Tran A, Heluwaert F, Plages A, Zarski JP

Gastroenterol Clin Biol. 2009 Oct-Nov;33(10-11):984-6

Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study.

Barbare JC, Bouché O, Bonnetain F, Dahan L, Lombard-Bohas C, Faroux R, Raoul JL, Cattan S, Lemoine A, Blanc JF, Bronowicki JP, Zarski JP, Cazorla S, Gargot D, Thevenot T, Diaz E, Bastie A, Aparicio T, Bedenne L

Eur. J. Cancer. 2009 Jul;45(10):1788-97

Telaprevir and peginterferon with or without ribavirin for chronic HCV infection.

Hezode C, Forestier N, Dusheiko G, Ferenci P, Pol S, Goeser T, Bronowicki JP, Bourliere M, Gharakhanian S, Bengtsson L, McNair L, George S, Kieffer T, Kwong A, Kauffman RS, Alam J, Pawlotsky JM, Zeuzem S

N Engl J Med. 2009 Apr 30;360(18):1839-50.

[Management of chronic hepatitis C which failed to respond to previous treatment]

Bronowicki JP, Nani A, Barraud H

Gastroenterol Clin Biol. 2009 Apr;33(4):345-52

Interaction of ribavirin with azathioprine metabolism potentially induces myelosuppression.

Peyrin-Biroulet L, Cadranel JF, Nousbaum JB, Oussalah A, Seddik M, Canva V, Cortot A, Sogni P, Gueant JL, Bigard MA, Roblin X, Bronowicki JP

Aliment Pharmacol Ther. 2008 Oct 15;28(8):984-93

Methylenetetrahydrofolate reductase 677 T allele protects against persistent HBV infection in West Africa

Bronowicki JP, Abdelmouttalebl D, Peyrin-Biroulet L, Venard V, Khiri H, Chabi N, Amouzou EK, Barraud H, Halfon P, Sanni A, Bigard MA, Le Faou A, Gueant JL

J Hepatol. 2008 Apr;48(4):532-9

Hepatitis C: which strategy in case of treatment failure?

Bronowicki JP, Larrey D, Tran A, Perronne C, Denis J, Cadranel JF, Trepo C

Gastroenterol Clin Biol. 2008 Mar;32(3 Pt 2):S109-16.

Multicentre randomised phase III trial comparing Tamoxifen alone or with Transarterial Lipiodol Chemoembolisation for unresectable hepatocellular carcinoma in cirrhotic patients (Federation Francophone de Cancerologie Digestive 9402).

Doffoel M, Bonnetain F, Bouche O, Vetter D, Abergel A, Fratte S, Grange JD, Stremsdoerfer N, Blanchi A, Bronowicki JP, Caroli-Bosc FX, Causse X, Masskouri F, Rougier P, Bedenne L

Eur J Cancer. 2008 Mar;44(4):528-38

Association of MTRR 66A>G polymorphism with superoxide dismutase and disease activity in patients with Crohn's disease.

Peyrin-Biroulet L, Guéant-Rodriguez RM, Chen M, Bronowicki JP, Bigard MA, Guéant JL

Am. J. Gastroenterol.. 2008 Feb;103(2):399-406

Methionine synthase A2756G polymorphism may predict ulcerative colitis and methylenetetrahydrofolate reductase C677T pancolitis, in Central China.

Chen M, Peyrin-Biroulet L, Xia B, Gueant-Rodriguez RM, Bronowicki JP, Bigard MA, Gueant JL

BMC Med Genet. 2008 Aug 13;9:78.

[Is it possible to stop nucleos(t)ide analogue based therapy in chronic hepatitis B?]

Bronowicki JP, Nani A, Barraud H, Cadranel JF

Gastroenterol Clin Biol. 2008 Jan;32(1 Pt 2):S50-5.

UDP-glucuronosyltransferase UGT1A7 genetic polymorphisms in hepatocellular carcinoma: a differential impact according to seropositivity of HBV or HCV markers?

Stucker I, Loriot MA, N'Koutchou G, Cenee S, Bodin L, Mulot C, Gelu-Simeon M, Pelletier L, Bronowicki JP, Degos F, Beaune P, Laurent-Puig P, Hemon D, Trinchet JC, Pelletier G

BMC Cancer. 2007 Nov 19;7:214.

Phase 2 study of the combination of merimepodib with peginterferon-alpha2b, and ribavirin in nonresponders to previous therapy for chronic hepatitis C.

Marcellin P, Horsmans Y, Nevens F, Grange JD, Bronowicki JP, Vetter D, Purdy S, Garg V, Bengtsson L, McNair L, Alam J

J Hepatol. 2007 Oct;47(4):476-83

Mice deficient in cystathionine beta synthase display altered homocysteine remethylation pathway.

Alberto JM, Hamelet J, Noll C, Blaise S, Bronowicki JP, Gueant JL, Delabar JM, Janel N

Mol Genet Metab. 2007 Aug;91(4):396-8

[Non invasive markers using for the assessment of fibrosis in hepatitis C]

Zarski JP, Bedossa P, Bronowicki JP, Doffoel M, Poynard T

Gastroenterol Clin Biol. 2007 Aug-Sep;31(8-9 Pt 3):4S34-9.

Diagnostic accuracy of the Multistix 8 SG reagent strip in diagnosis of spontaneous bacterial peritonitis.

Nousbaum JB, Cadranel JF, Nahon P, Khac EN, Moreau R, Thevenot T, Silvain C, Bureau C, Nouel O, Pilette C, Paupard T, Vanbiervliet G, Oberti F, Davion T, Jouannaud V, Roche B, Bernard PH, Beaulieu S, Danne O, Thabut D, Chagneau-Derrode C, de Ledinghen V, Mathurin P, Pauwels A, Bronowicki JP, Habersetzer F, Abergel A, Audigier JC, Sapey T, Grange JD, Tran A

Hepatology. 2007 May;45(5):1275-81.

Vascular and cellular stress in inflammatory bowel disease: revisiting the role of homocysteine.

Peyrin-Biroulet L, Rodriguez-Gueant RM, Chamaillard M, Desreumaux P, Xia B, Bronowicki JP, Bigard MA, Gueant JL

Am J Gastroenterol. 2007 May;102(5):1108-15

Peginterferon alpha-2b plus ribavirin for treatment of chronic hepatitis C with severe fibrosis: a multicentre randomized controlled trial comparing two doses of peginterferon alpha-2b.

Abergel A, Hezode C, Leroy V, Barange K, Bronowicki JP, Tran A, Alric L, Castera L, Bernard PH, Henquell C, Lafeuille H, Ughetto S, Darcha C, Chevallier M, Martineau N, Dubost S, Randl K, Dhumeaux D, Bommelaer G, Bonny C

J Viral Hepat. 2006 Dec;13(12):811-20.

[Epigenetic changes and liver carcinogenesis].

Peyrin-Biroulet L, Barraud H, Darfeuil F, Lefebvre M, Bigard MA, Gueant JL, Bronowicki JP

Gastroenterol Clin Biol. 2006 Dec;30(12):1354-9.

Colon cancer after infliximab therapy for Crohn's disease in a young patient transplanted for primary sclerosing cholangitis.

Peyrin-Biroulet L, Bressenot A, Chone L, Denjean P, Boissel P, Bigard MA, Bronowicki JP

Am J Gastroenterol. 2006 Nov;101(11):2664-5.

Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin.

Bronowicki JP, Ouzan D, Asselah T, Desmorat H, Zarski JP, Foucher J, Bourliere M, Renou C, Tran A, Melin P, Hezode C, Chevalier M, Bouvier-Alias M, Chevaliez S, Montestruc F, Lonjon-Domanec I, Pawlotsky JM

Gastroenterology. 2006 Oct;131(4):1040-8

Managing resistance to analogue antiviral drugs in a chronic compensated hepatitis B patient.

Bronowicki JP, Barraud H, Couzigou P

Gastroenterol Clin Biol. 2006 Oct;30(10 Pt 2):S17-9.

[Managing resistance to analogue antiviral drugs in a chronic compensated hepatitis B patient].

Bronowicki JP, Barraud H, Couzigou P

Gastroenterol Clin Biol. 2006 Oct;30(10 Pt 2):3S17-9.

Contribution of computed tomography with oral media contrast to the diagnosis of esophago-pericardial fistula.

Peyrin-Biroulet L, Bronowicki JP, Bigard MA, Regent D, Walter S, Platini C

Clin Imaging. 2006 Sep-Oct;30(5):347-9.

Effectiveness of interferon plus ribavirin combination in the treatment of naive patients with hepatitis C virus type 5. A French multicentre retrospective study.

Bonny C, Fontaine H, Poynard T, Hezode C, Larrey D, Marcellin P, Bourliere M, Bronowicki JP, Merle P, Zarski JP, Sapey T, Guillemard C, Ughetto S, Henquell C, Nicolas C, Roche C, Randl K, Bommelaer G, Abergel A

Aliment Pharmacol Ther. 2006 Aug 15;24(4):593-600.

[Antiviral treatments during cirrhosis].

Bronowicki JP

Gastroenterol Clin Biol. 2006 Jun-Jul;30(6-7):899-902.

[Hepatitis A acquired from an asymptomatic adopted child].

Peyrin-Biroulet L, Donnais A, Barraud H, Darfeuil F, Watelet J, Hudziak H, Bronowicki JP, Bigard MA, Chone L

Gastroenterol Clin Biol. 2006 Apr;30(4):609-10.

Prevalence of methylenetetrahydrofolate reductase 677T and 1298C alleles and folate status: a comparative study in Mexican, West African, and European populations.

Gueant-Rodriguez RM, Gueant JL, Debard R, Thirion S, Hong LX, Bronowicki JP, Namour F, Chabi NW, Sanni A, Anello G, Bosco P, Romano C, Amouzou E, Arrieta HR, Sanchez BE, Romano A, Herbeth B, Guilland JC, Mutchinick OM

Am J Clin Nutr. 2006 Mar;83(3):701-7.

[Intestinal permeability and cirrhosis].

Ancel D, Barraud H, Peyrin-Biroulet L, Bronowicki JP

Gastroenterol Clin Biol. 2006 Mar;30(3):460-8.

Comparison of outcome in patients with cirrhosis and ascites following treatment with albumin or a synthetic colloid: a randomised controlled pilot trail.

Moreau R, Valla DC, Durand-Zaleski I, Bronowicki JP, Durand F, Chaput JC, Dadamessi I, Silvain C, Bonny C, Oberti F, Gournay J, Lebrec D, Grouin JM, Guemas E, Golly D, Padrazzi B, Tellier Z

Liver Int. 2006 Feb;26(1):46-54.

[Complementary treatments of chronic viral hepatitis C].

Thevenot T, Di Martino V, Lunel-Fabiani F, Vanlemmens C, Becker MC, Bronowicki JP, Bresson-Hadni S, Miguet JP

Gastroenterol Clin Biol. 2006 Feb;30(2):197-214.

Digestive endoscopy and HCV transmission.

Bronowicki JP

J Hepatol. 2006 Jan;44(1):246-7.

[Managing the complications of cirrhosis].

Deltenre P, Mathurin P, Barraud H, Bronowicki JP, Jacquet E, Puche P, Jaber S, Navarro F, Pageaux GP

Rev Prat. 2005 Sep 30;55(14):1555-63.

[What monitoring for the cirrhosis patient?].

Barraud H, Bronowicki JP

Rev Prat. 2005 Sep 30;55(14):1558-9.

Mild neonatal hypoxia exacerbates the effects of vitamin-deficient diet on homocysteine metabolism in rats.

Blaise S, Alberto JM, Nedelec E, Ayav A, Pourie G, Bronowicki JP, Gueant JL, Daval JL

Pediatr Res. 2005 Jun;57(6):777-82

[Mediastinal lymph node and vertebral metastases 3 years after liver transplantation for cholangiocarcinoma: 2 unusual localizations].

Peyrin-Biroulet L, Bronowicki JP, Cinqualbre J, Gendrault P, Graff-Cailleaud P, Marchal C

Gastroenterol Clin Biol. 2005 Apr;29(4):469-71.

[Hepatotoxicity associated with herbal remedies: clinical, biological, histological data and the mechanisms involved in some typical examples].

Peyrin-Biroulet L, Barraud H, Petit-Laurent F, Ancel D, Watelet J, Chone L, Hudziak H, Bigard MA, Bronowicki JP

Gastroenterol. Clin. Biol.. ;28(6-7 Pt 1):540-50

Pr BRONOWICKI Jean-Pierre

Fiche personne

coordonnées

Territoire

Statut

affiliation

équipes/plateformes

Recherche

Publications